Drug Trial Radar · NCT04632966
Safety Study of PTP-001 for Treating Knee Osteoarthritis
Last checked: Nov 19, 2026Latest source record: Dec 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Actual
Start
Feb 26, 2021
Primary completion
Sep 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- Bioventus LLCIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of safety, tolerability, and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in individuals with knee osteoarthritis (OA).
Conditions
- Knee Osteoarthritis
Interventions
Biological: PTP-001Biological
allogeneic placental tissue particulate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of local and systemic treatment emergent adverse events (AEs) and incidence of abnormal laboratory and immunogenicity panelsTime frame: Baseline to Week 52
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
James R. Urbaniak, MD, Duke Sports Science Institute
Durham, North Carolina
Coastal Carolina Research Center
North Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.